6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
AssigneePfizer Inc.
InventorsThomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Travis T. Wager, Matthew Merrill Hayward
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R2, R3, and R4 are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
Claims27
A compound of Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is a substituent selected from the group consisting of (C3-C8)cycloalkyl, (4- to 10-membered)heterocycloalkyl, (C6-C10)aryl, and (5- to 10-membered)heteroaryl, wherein the (C3-C8)cycloalkyl, (4- to 10-membered)heterocycloalkyl, (C6-C10)aryl and (5- to 10-membered)heteroaryl are optionally substituted with one to five R5;
- R2 and R3 are each independently selected from the group consisting of hydrogen, optionally substituted (C1-C6)alkyl, (C3-C8)cycloalkyl, (4- to 10-membered)heterocycloalkyl, (C6-C10)aryl, and (5- to 10-membered)heteroaryl, wherein the (C3-C8)cycloalkyl, (4- to 10-membered)heterocycloalkyl, (C6-C10)aryl, and (5- to 10-membered)heteroaryl are optionally substituted with one to five R6;
- or
- R2 and R3 taken together with the nitrogen to which they are attached form a (4- to 10-membered)heterocycloalkyl or a (5- to 10-membered)heteroaryl, wherein the (4- to 10-membered)heterocycloalkyl and (5- to 10-membered)heteroaryl are optionally substituted with one to five R6;
- when present, R4, at each occurrence, is independently selected from the group consisting of halogen, cyano, hydroxy, —SF5, nitro, optionally substituted (C1-C6)alkyl, optionally substituted (C2-C6)alkenyl, optionally substituted (C2-C6)alkynyl, optionally substituted (C1-C6)alkylthio, optionally substituted (C1-C6)alkoxy, —N(R7)(R8), —N(R7)(C═(O)R8), —C(═O)N(R7)(R8), —O—C(═O)—N(R7)(R8), —C(═O)—R7, and —C(═O)—OR7;
- when present, R5 and R6, at each occurrence, are independently selected from the group consisting of halogen, oxo, cyano, hydroxy, —SF5, nitro, optionally substituted (C1-C6)alkyl, optionally substituted (C2-C6)alkenyl, optionally substituted (C2-C6)alkynyl, optionally substituted (C1-C6)alkylthio, optionally substituted (C1-C6)alkoxy, —N(R7)(R8), —N(R7)(C═(O)R8), —C(═O)N(R7)(R8), —O—C(═O)—N(R7)(R8), —C(═O)—R7, and —C(═O)—OR7;
- R7 and R8 at each occurrence are independently selected from the group consisting of hydrogen and (C1-C6)alkyl;
- and
- a is represented by an integer selected from 0, 1, 2 or 3.
(canceled)
(canceled)
9-11. (canceled)
(canceled)
(canceled)
(canceled)
23-24. (canceled)
26-30. (canceled)
32-34. (canceled)
Dependencies are inferred from the claim text.